Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

agitation

- PMLiVE

Interview: Mike Hutton, Lilly

Lilly’s chief scientific officer for neurodegenerative diseases talks about his hopes for Alzheimer’s research and making the move from academia to pharma

- PMLiVE

Dementia map reveals extent of under-diagnosis

Less than half of patients in England are diagnosed

- PMLiVE

FDA approves Alzheimer’s diagnostic drug

GE Healthcare's Vizamyl to compete with Lilly's Amyvid

- PMLiVE

Lundbeck and Otsuka take Alzheimer’s drug into phase III

Lu AE58054 affects levels of serotonin in the brain

- PMLiVE

Novo backs Victoza’s prospects in Alzheimer’s

Chief science officer says phase III trial could begin in three years

- PMLiVE

US NIH provides $45m for Alzheimer’s research

Projects will investigate basic science of the neurological condition

- PMLiVE

Novo Nordisk’s Victoza shows Alzheimer’s benefits

UK scientists say the diabetes drug could reverse effects of dementia

- PMLiVE

Alzheimer’s disease pipeline takes multiple hits

Following a number of recent failures of clinical compounds, researchers are shifting the focus from late-stage disease to early-stage or prophylactic therapies

- PMLiVE

FDA fast-tracks Elan’s Alzheimer’s drug

Speeds up regulatory process for ELND005 for the treatment of neuropsychiatric symptoms

- PMLiVE

Merck maintains lead in BACE inhibitors for Alzheimer’s

Positive results in phase Ib study in patients with Alzheimer’s disease

- PMLiVE

Safety fears force Lilly to halt BACE inhibitor trial in Alzheimer’s

Patients experience abnormal liver functions in trial

- PMLiVE

Baxter’s Gammagard latest disappointment in Alzheimer’s

Fails to show improvement in cognitive and functional measures

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links